Gapping up
In reaction to strong earnings/guidance:
- IBM +5.8%, ADTN +4.8%, SVU +4.2%, IBKR +3.2%, UFPI +2.6%, ABT +1.7%, NAVI +1.2%, OMAB +1.2%, PZG +1.1%, CP +1%
Other news:
- PLX +35.3% (announces an Ex-US license and collaboration agreement with Chiesi Farmaceutici for pegunigalsidase alfa)
- SSKN +31.4% (thinly traded; announces agreement with MedResults Network that will enhance sales efforts of Nordlys and STRATAPEN )
- SPPI +31.4% (reports new data for Poziotinib; demonstrates evidence of significant antitumor activity)
- RXDX +31.4% (reports data for Entrectinib demonstrated a 78% and 69% confirmed ORR)
- TROV +17.7% (announces 'positive' data from preclinical research demonstrating synergy of PCM-075)
- DRIO +16.1% (receives CE Mark for its Lightning-enabled version of the Dario Blood Glucose Monitoring System )
- BNTC +11.9% (confirms new patent relating to the Company's hepatitis B program has been issued in the United States)
- LTBR +11.7% (received a Notice of Allowance in the China for another key patent relating to its metallic fuel design)
- HCLP +11.1% (resumes distribution for the third quarter of 2017 and announces unit buyback program -- declared a quarterly cash distribution of $0.15 per unit on all common units, approved a unit buyback program of up to $100 million)
- ABUS +7.8% (announces a collaboration and license agreement w/ Gritstone Oncology)
- LPCN +5.1% (FDA has scheduled the Bone, Reproductive and Urologic Drugs Advisory Committee meeting on January 10, 2018 to discuss the New Drug Application for TLANDO)
- FMSA +4% (HCLP sympathy)
- INO +3.4% (was initiated after the close with Outperform rating and $11 tgt at RBC Capital Mkts)
- PRKR +3.3% (enters into common stock purchase agreement with Aspire Capital for a private placement of 312,500 shares of common stock at $1.60 per share)
- JUNO +2.7% (enters a license agreement for the Trianni Mouse
- SLCA +2.2% (HCLP sympathy)
- CVS +1.5% (announces five-year agreement with Anthem (ANTM) to provide services to support IngenioRx)
- FGEN +1.3% (announces that the CFDA has accepted the co's recently submitted New Drug Application for registration of roxadustat)
- QURE +1.1% (presents preclinical data on AMT-130)
- ALNY +1.1% (announces licensing agreement with Vir Biotechnologyfor the development and commercialization of RNAi therapeutics for infectious diseases)
- PYPL +0.9% (following JPM/WePay news)
Analyst comments:
- LSCC +4.5% (upgraded to Buy from Hold at Jefferies)
- GPRO +4.4% (upgraded to Buy from Neutral at Longbow)
- FTNT +3.1% (upgraded to Buy from Hold at Deutsche Bank)
- SYNT +2.7% (upgraded to Outperform from Mkt Perform at William Blair)
- MGA +2.4% (upgraded to Buy from Underperform at BofA/Merrill)
- EQIX +1.8% (upgraded to Overweight from Equal Weight at Barclays)
- MRK +1.6% (upgraded to Buy from Neutral at Citigroup)
- MET +1.2% (initiated on the Conviction Buy List at Goldman)
